Phase III
Discover what’s in store for today’s presentations at The American Academy of Neurology’s annual meeting, which will include data for a variety of neurological treatments.
Theravance Biopharma announced mixed results from a study evaluating the use of ampreloxetine to reduce symptomatic neurogenic orthostatis hypotension (nOH).
The delay is related to a third-party secondary packaging and labeling facility that Alnylam planned to use for the launch of vutrisiran.
New data from Roche’s study on the use of Ocrevus to treat patients with primary and secondary progressive multiple sclerosis demonstrated positive outcomes.
Fabry disease treatment is going to get new updates as Protalix and Chiesi are seeking approval. This can be a game-changer in the market. Here’s more about it.
The 2022 American Academy of Neurology (AAN) Annual Meeting kicked off on Saturday and will continue on through Thursday.
Three studies supporting Merck and Ridgeback Biotherapeutics’ Lagevrio (molnupiravir) will be presented at the ECCMID 2022 in Lisbon from April 23-26.
Mavacamten is often referred to as “first-in-class” because it addresses the root cause of obstructions. Here’s everything you should know about its recent progress.
The 71st annual American College of Cardiology’s Scientific Session saw several wins over the weekend, led by some of the life sciences industries’ largest companies.
After wrapping up March with a flurry of PDUFA dates, the U.S. Food and Drug Administration has a more leisurely calendar for the first three weeks of April, at least in terms of drug approvals.
PRESS RELEASES